Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1 Filing based on four Phase 3 studies that met all primary and co-primary endpoints.

Social Security beneficiaries would welcome extra money in the bank from a COLA hike. But some might only be looking at $50 a ...